# Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

> **NCT00866749** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (actual)

## Conditions studied

- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Daunorubicin
- **DRUG:** Vincristine
- **DRUG:** PEG-asparaginase
- **DRUG:** Intrathecal Methotrexate
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Doxorubicin
- **DRUG:** Thioguanine

## Key facts

- **NCT ID:** NCT00866749
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-12
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866749, "Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00866749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*